Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 207

1.

Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting.

Gamucci T, Pizzuti L, Sperduti I, Mentuccia L, Vaccaro A, Moscetti L, Marchetti P, Carbognin L, Michelotti A, Iezzi L, Cassano A, Grassadonia A, Astone A, Botticelli A, Magnolfi E, Di Lauro L, Sergi D, Fuso P, Tinari N, Barba M, Maugeri-Saccà M, Landucci E, Conti F, Sanguineti G, De Tursi M, Iafrate G, Giordano A, Ciliberto G, Natoli C, Vici P.

J Cell Physiol. 2018 Mar;233(3):2313-2323. doi: 10.1002/jcp.26103. Epub 2017 Sep 27.

PMID:
28710865
2.

Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.

Tan QX, Qin QH, Yang WP, Mo QG, Wei CY.

Int J Clin Exp Pathol. 2014 Sep 15;7(10):6862-70. eCollection 2014.

3.

Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.

Masuda H, Brewer TM, Liu DD, Iwamoto T, Shen Y, Hsu L, Willey JS, Gonzalez-Angulo AM, Chavez-MacGregor M, Fouad TM, Woodward WA, Reuben JM, Valero V, Alvarez RH, Hortobagyi GN, Ueno NT.

Ann Oncol. 2014 Feb;25(2):384-91. doi: 10.1093/annonc/mdt525. Epub 2013 Dec 18.

4.

Sequential adjuvant docetaxel and anthracycline chemotherapy for node positive breast cancers: a retrospective study.

Bulent Akinci M, Algin E, Inal A, Odabas H, Berk V, Coskun U, Uyeturk U, Isikdogan A, Aksoy S, Civelek B, Sevinc A, Buyukberber S.

J BUON. 2013 Apr-Jun;18(2):314-20.

PMID:
23818340
5.

Prognostic factors in operable breast cancer treated with neoadjuvant chemotherapy: towards a quantification of residual disease.

Mombelli S, Kwiatkowski F, Abrial C, Wang-Lopez Q, de Boissieu P, Garbar C, Bensussan A, Curé H.

Oncology. 2015;88(5):261-72. doi: 10.1159/000368557. Epub 2015 Jan 8.

PMID:
25573741
6.

Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy.

Ács B, Zámbó V, Vízkeleti L, Szász AM, Madaras L, Szentmártoni G, Tőkés T, Molnár BÁ, Molnár IA, Vári-Kakas S, Kulka J, Tőkés AM.

Diagn Pathol. 2017 Feb 21;12(1):20. doi: 10.1186/s13000-017-0608-5.

7.

Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact.

Nabholtz JM, Abrial C, Mouret-Reynier MA, Dauplat MM, Weber B, Gligorov J, Forest AM, Tredan O, Vanlemmens L, Petit T, Guiu S, Van Praagh I, Jouannaud C, Dubray-Longeras P, Tubiana-Mathieu N, Benmammar KE, Kullab S, Bahadoor MR, Radosevic-Robin N, Kwiatkowski F, Desrichard A, Cayre A, Uhrhammer N, Chalabi N, Chollet P, Penault-Llorca F.

Ann Oncol. 2014 Aug;25(8):1570-7. doi: 10.1093/annonc/mdu183. Epub 2014 May 14.

PMID:
24827135
9.

Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study.

de Nonneville A, Gonçalves A, Zemmour C, Cohen M, Classe JM, Reyal F, Colombo PE, Jouve E, Giard S, Barranger E, Sabatier R, Bertucci F, Boher JM, Houvenaeghel G.

Eur J Cancer. 2017 Oct;84:34-43. doi: 10.1016/j.ejca.2017.06.043. Epub 2017 Aug 4.

PMID:
28780480
10.

Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer.

Matsubara N, Mukai H, Fujii S, Wada N.

Breast Cancer Res Treat. 2013 Jan;137(1):203-12. doi: 10.1007/s10549-012-2344-6. Epub 2012 Nov 27.

PMID:
23184081
11.

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Konecny GE, Denkert C, Nekljudova V, Mehta K, Loibl S.

J Clin Oncol. 2012 May 20;30(15):1796-804. doi: 10.1200/JCO.2011.38.8595. Epub 2012 Apr 16.

PMID:
22508812
12.

Neoadjuvant chemotherapy-induced changes in immunohistochemical expression of estrogen receptor, progesterone receptor, HER2, and Ki-67 in patients with breast cancer.

Avci N, Deligonul A, Tolunay S, Cubukcu E, Fatih Olmez O, Ulas A, Hartavi M, Kurt E, Evrensel T.

J BUON. 2015 Jan-Feb;20(1):45-9.

PMID:
25778295
13.

Neoadjuvant, anthracycline-free chemotherapy with carboplatin and docetaxel in triple-negative, early-stage breast cancer: a multicentric analysis of rates of pathologic complete response and survival.

Kern P, Kalisch A, von Minckwitz G, Pütter C, Kolberg HC, Pott D, Kurbacher C, Rezai M, Kimmig R.

J Chemother. 2016 Jun;28(3):210-7. doi: 10.1179/1973947815Y.0000000061. Epub 2016 May 27.

PMID:
26239282
14.

Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer.

Natoli C, Vici P, Sperduti I, Grassadonia A, Bisagni G, Tinari N, Michelotti A, Zampa G, Gori S, Moscetti L, De Tursi M, Panebianco M, Mauri M, Ferrarini I, Pizzuti L, Ficorella C, Samaritani R, Mentuccia L, Iacobelli S, Gamucci T.

J Cancer Res Clin Oncol. 2013 Jul;139(7):1229-40. doi: 10.1007/s00432-013-1436-y. Epub 2013 Apr 20.

15.

Evaluation with 3.0-T MR imaging: predicting the pathological response of triple-negative breast cancer treated with anthracycline and taxane neoadjuvant chemotherapy.

Kim MJ, Kim EK, Park S, Moon HJ, Kim SI, Park BW.

Acta Radiol. 2015 Sep;56(9):1069-77. doi: 10.1177/0284185114548507. Epub 2014 Sep 16.

PMID:
25228161
16.
17.

A retrospective analysis of adjuvant CAF, AC-T and TAC regimens in triple negative early stage breast cancer.

Buyukhatipoglu H, Babacan T, Kertmen N, Balakan O, Suner A, Ates O, Sarici F, Aslan A, Diker O, Tasdemir V, Ozisik Y, Altundag K.

J BUON. 2015 Jan-Feb;20(1):22-7.

PMID:
25778291
18.

Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers.

Krishnamurti U, Wetherilt CS, Yang J, Peng L, Li X.

Hum Pathol. 2017 Jun;64:7-12. doi: 10.1016/j.humpath.2017.01.004. Epub 2017 Jan 30.

PMID:
28153508
19.
20.

Comparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast Cancers.

Lee HJ, Park IA, Song IH, Kim SB, Jung KH, Ahn JH, Ahn SH, Kim HH, Gong G.

PLoS One. 2015 Sep 22;10(9):e0137885. doi: 10.1371/journal.pone.0137885. eCollection 2015.

Supplemental Content

Support Center